Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/IRCT20170207032444N3
IRCT20170207032444N3RecruitingPhase 3

The efficacy and safety of Thalidomide in severe Covid19 pneumonia: Arandomized controlled clinical trial

Esfahan University of Medical Sciences0 sites60 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 3
Status
Recruiting
Enrollment
60
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 years to 75 years (—)
Sex
All

Inclusion Criteria

  • •18-75 year old men and 50-75 year old women admitted in hospital
  • •Spo2 less than 85% in admission
  • •Clinical symptoms and signs compatible with COVID19 infection and positive PCR test or lung HRCT abnormalities compatible with COVID19 pneumonia
  • •No need to intubation in first 24 hour of admission
  • •No multiorgan failure at presentation
  • •No shock state at presentation
  • •Obtained informed consent

Exclusion Criteria

  • •Hepatic failure (Child Pugh score = C, AST> 5 times of the upper limit normal)
  • •Severe renal dysfunction (GFR less than 30cc per min)

Investigators

Similar Trials

Active, not recruiting
Phase 1
Efficacy of thalidomide in the treatment of heavy and frequent nose bleeding in patients affected by hereditary hemorrhagic telangiectasiaSevere recurrent epistaxis in hereditary hemorrhagic telangiectasiaMedDRA version: 14.1Level: LLTClassification code 10038554Term: Rendu-Osler-Weber syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2011-004096-36-ITOSPEDALE POLICLINICO S. MATTEO31
Active, not recruiting
Phase 1
The use of Thalidomide as a treatment for the cachexia of incurable upper gastrointestinal adenocarcinomas:a randomised, double-blinded, placebo controlled trial. - Thalidomide in cancer cachexia
EUCTR2005-000371-18-GBPortsmouth Hospitals Trust180
Completed
Phase 3
Effect of Thalidomide in Covid 19 pneumoniaPneumonia caused by Coronavirus 2019, COVID19.Coronavirus infection, unspecifiedB34.2
IRCT20200428047232N1Esfahan University of Medical Sciences60
Recruiting
Phase 2
se of thalidomide in complicated tubercular infection of brai
CTRI/2023/05/052417PGIMER Chandigarh
Not yet recruiting
Not Applicable
Addition of oral thalidomide to standard antitubercular regimen for initial 2 months improves the outcome in patients of tubercular meningitis as compared to standard therapy alone.
CTRI/2020/08/027438AIIMS Bhubaneswar